At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 123 enrolled
Drug / intervention
Pimavanserin tartrate (ACP-103) +2 moredrug
Likely dose
Pimavanserin tartrate (ACP-103) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
In Brief
A Phase 3 clinical trial evaluating Pimavanserin tartrate (ACP-103) for Parkinson's Disease Psychosis. Completed, enrolled 123 participants across 50 sites in 9 countries.
Detailed Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease Psychosis
CountriesAustria, Belgium, Italy, Poland, Portugal, Serbia, Spain, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.2 years ago
Interventions
Pimavanserin tartrate (ACP-103)drug
10 mg, tablet, once daily by mouth, for six weeks
Pimavanserin tartrate (ACP-103)drug
20 mg, tablet, once daily by mouth, for six weeks
Pimavanserin tartrate (ACP-103)drug
Placebo, tablet, once daily by mouth, for six weeks